Derek Cowsert

News

Elacestrant Improves PFS vs Endocrine Monotherapy in ER-Positive/HER2-Negative Advanced Breast Cancer

07/12/2022

Elacestrant yielded improved PFS vs endocrine monotherapy as treatment for patients with ER-positive/HER2-negative advanced breast cancer in the phase 3 EMERALD trial.

Elacestrant yielded improved PFS...

07/12/2022

Oncology

News

Electronic Total Tumor-Infiltrating Lymphocytes Predict Risk of Relapse in Patients With Melanoma

11/18/2022

Derek Cowsert ;

Study findings demonstrate the efficacy of electronic total tumor-infiltrating lymphocytes for predicting potential relapse prognoses in patients with melanoma.

Study findings demonstrate the...

11/18/2022

Oncology

News

04/14/2023

Derek Cowsert ;

Pooled data from 3 randomized clinical trials demonstrated an association between improved survival outcomes in patients with non-small cell lung cancer and mild to moderate immune-related adverse events related to treatment with atezolizumab.

Pooled data from 3 randomized...

04/14/2023

Oncology

News

Anlotinib Proves Safe and Effective as First- and Second-Line Treatment for SCLC

08/09/2022

Derek Cowsert ;

A recent real-world observational study found anlotinib exhibited promising efficacy and safety for patients with small-cell lung cancer.

A recent real-world...

08/09/2022

Oncology

News

Optimal Surgery and Treatment Options for Stage 1 Lung Adenocarcinoma/Tumors Spread Through Air Spaces

02/22/2023

Derek Cowsert ;

A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.

A study found no difference in...

02/22/2023

Oncology

News

Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease

06/16/2022

Derek Cowsert ;

Study findings reveal treatment with stereotactic radiosurgery was associated with equitable survival outcomes vs whole brain radiotherapy for intracranial metastatic disease in patients with SCLC.

Study findings reveal treatment...

06/16/2022

Oncology

News

Apatinib Plus Pegylated Liposomal Doxorubicin Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian Cancer

10/27/2022

Derek Cowsert ;

Study findings show apatinib plus pegylated liposomal doxorubicin yields promising results in efficacy and safety among patients with platinum-resistant ovarian cancer.

Study findings show apatinib...

10/27/2022

Oncology

News

Alisertib Did Not Restore Fulvestrant Sensitivity Among Patients With Endocrine-Resistant, HER2-Negative Breast Cancer

04/17/2023

Derek Cowsert ;

The addition of fulvestrant to alisertib did not cause a statistically significant increase of objective response rate or progression-free survival for patients with endocrine-resistant, HER2-negative metastatic breast cancer.

The addition of fulvestrant to...

04/17/2023

Oncology

News

Aumolertinib vs Gefitinib as First-Line Treatment for Patients With EFGR-Mutated NSCLC

07/06/2022

Derek Cowsert ;

Study findings reveal first-line treatment with aumolertinib was associated with improved survival outcomes compared to gefitinib in patients with EFGR-mutated NSCLC.

Study findings reveal first-line...

07/06/2022

Oncology

News

FDA Approves Cemiplimab Plus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer

11/09/2022

Derek Cowsert ;

On November 8, 2022, the FDA approved cemiplimab-rwlc, 350 mg intravenously every 3 weeks, in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.

On November 8, 2022, the FDA...

11/09/2022

Oncology